10x Genomics TXG
Nasdaq · Laboratory Analytical Instruments · $7.0BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $490.5M | $516.4M | $618.7M | $610.8M | $642.8M | +5.2% | +7.0% | |
| Cost of Revenue (COGS) | $74.1M | $120.4M | $209.4M | $196.3M | $198.9M | +1.3% | +28.0% | |
| Gross Profit | $416.4M | $396.0M | $409.3M | $414.5M | $443.9M | +7.1% | +1.6% | |
| Selling, General & Admin (SG&A) | $257.6M | $298.3M | $343.3M | $344.3M | $316.1M | −8.2% | +5.3% | |
| Total Operating Expenses | $468.7M | $564.0M | $674.6M | $609.0M | $504.9M | −17.1% | +1.9% | |
| Operating Income (EBIT) | $-52.3M | $-167.9M | $-265.3M | $-194.6M | $-61.0M | +68.7% | — | |
| Interest Expense | $866,000 | $476,000 | $33,000 | $4,000 | $0 | −100.0% | — | |
| Income Tax Expense | $4.5M | $4.0M | $6.3M | $4.9M | $3.6M | −26.2% | −5.2% | |
| GAAP Net Income | $-58.2M | $-166.0M | $-255.1M | $-182.6M | $-43.5M | +76.2% | — | |
| Diluted EPS | $-0.53 | $-1.46 | $-2.18 | $-1.52 | $-0.35 | +77.0% | — | |
| Diluted Shares | 110.3M | 113.9M | 117.2M | 120.5M | 124.7M | +3.6% | +3.1% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $596.1M | $227.4M | $359.3M | $344.1M | $474.0M | +37.8% | −5.6% | |
| Inventory | $60.0M | $81.6M | $73.7M | $83.1M | $56.3M | −32.2% | −1.5% | |
| Total Current Assets | $747.6M | $635.0M | $596.0M | $584.4M | $684.5M | +17.1% | −2.2% | |
| Total Assets | $1.0B | $1.0B | $965.1M | $918.6M | $1.0B | +13.4% | +0.5% | |
| Total Current Liabilities | $110.4M | $131.0M | $127.2M | $117.6M | $153.5M | +30.5% | +8.6% | |
| Total Debt (Short + Long Term) | $0 | $0 | $0 | $0 | $0 | — | — | |
| Total Liabilities | $201.3M | $223.2M | $224.1M | $208.5M | $245.0M | +17.5% | +5.0% | |
| Stockholders' Equity | $817.6M | $805.7M | $741.0M | $710.1M | $796.3M | +12.1% | −0.7% | |
| Net Cash / (Net Debt) | $596.1M | $227.4M | $359.3M | $344.1M | $474.0M | +37.8% | −5.6% | |
| Invested Capital | $221.5M | $578.4M | $381.8M | $366.1M | $322.4M | −11.9% | +9.8% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $-21.4M | $-33.6M | $-15.2M | $6.7M | $136.1M | +1941.6% | — | |
| Depreciation & Amortization (D&A) | $21.1M | $25.4M | $35.5M | $35.9M | $36.2M | +0.9% | +14.4% | |
| Stock-Based Compensation (SBC) | $96.0M | $136.8M | $166.9M | $140.7M | $109.1M | −22.5% | +3.3% | |
| Capital Expenditures (CapEx) | $101.3M | $131.7M | $48.6M | $12.4M | $5.9M | −52.1% | −50.8% | |
| Free Cash Flow (FCF) | $-122.7M | $-165.3M | $-63.8M | $-5.7M | $130.1M | +2371.2% | — | |
| True FCF (ex-SBC Owner Cash) | $-218.6M | $-302.1M | $-230.7M | $-146.5M | $21.0M | +114.3% | — | |
| Share Repurchases (Buybacks) | — | — | — | — | $80,000 | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.